NASDAQ$BBNX
Beta Bionics Inc · Q1 2026 earnings
Q1 2026 earnings ·
Briefing
BBNX reported Q1 2026 net sales of $27.6M with a net loss of $21.9M and diluted loss per share of $0.49.
Beta Bionics posted Q1 2026 net sales of $27.6 million (+57% YoY) as iLet adoption grew, including a higher mix of pharmacy-benefit-plan channel sales. Gross profit was $16.4 million versus $9.0 million a year ago, but operating loss widened to $24.3 million on higher R&D and sales and marketing spend. Net loss was $21.9 million, or $0.49 per diluted share, compared with $28.7 million and $0.93 per share in Q1 2025.
- Net sales $27.6M (+57% YoY); gross profit $16.4M.
- Operating loss $(24.3)M on elevated commercialization spend.
- Net loss $(21.9)M; diluted EPS $(0.49) vs. $(0.93).
- PBP channel was 39% of sales vs. 22% prior year.
Headline financials
Revenue & EPS history
Beta Bionics Inc · Revenue · Quarterly
$27.6M
Forward guidance
The 10-Q discusses commercialization, reimbursement mix, and clinical pipeline milestones without numeric consolidated EPS guidance.
Tailwinds
- Strong top-line growth and improved gross profit dollars.
- Loss narrowed versus prior-year quarter.
Headwinds
- Still GAAP unprofitable with heavy R&D and S&M.
- Reimbursement and payer mix shift can pressure near-term margins.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports · overlaid with Q1 2026
-0.7%
Avg return
Earnings day
+7.3%
Avg return
5 days after
+18.0%
Avg return
30 days after
40%
2 / 5 earnings
Positive
+4.8%
Q2 2025
Best reaction
-5.0%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.0% | -13.5% | -17.7% | |
| Q4 2025 | -2.6% | -1.5% | -23.4% | |
| Q3 2025 | +2.2% | +14.6% | +29.9% | |
| Q2 2025 | +4.8% | +17.2% | +33.7% | |
| Q1 2025 | -2.8% | +19.4% | +67.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro